Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 17.42 EUR 1.52% Market Closed
Market Cap: 509.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Intrinsic Value

The intrinsic value of one MEDCL stock under the Base Case scenario is 26.36 EUR. Compared to the current market price of 17.42 EUR, Medincell SA is Undervalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MEDCL Intrinsic Value
26.36 EUR
Undervaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Medincell SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MEDCL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MEDCL?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Medincell SA

Provide an overview of the primary business activities
of Medincell SA.

What unique competitive advantages
does Medincell SA hold over its rivals?

What risks and challenges
does Medincell SA face in the near future?

Has there been any significant insider trading activity
in Medincell SA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medincell SA.

Provide P/S
for Medincell SA.

Provide P/E
for Medincell SA.

Provide P/OCF
for Medincell SA.

Provide P/FCFE
for Medincell SA.

Provide P/B
for Medincell SA.

Provide EV/S
for Medincell SA.

Provide EV/GP
for Medincell SA.

Provide EV/EBITDA
for Medincell SA.

Provide EV/EBIT
for Medincell SA.

Provide EV/OCF
for Medincell SA.

Provide EV/FCFF
for Medincell SA.

Provide EV/IC
for Medincell SA.

Show me price targets
for Medincell SA made by professional analysts.

What are the Revenue projections
for Medincell SA?

How accurate were the past Revenue estimates
for Medincell SA?

What are the Net Income projections
for Medincell SA?

How accurate were the past Net Income estimates
for Medincell SA?

What are the EPS projections
for Medincell SA?

How accurate were the past EPS estimates
for Medincell SA?

What are the EBIT projections
for Medincell SA?

How accurate were the past EBIT estimates
for Medincell SA?

Compare the revenue forecasts
for Medincell SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medincell SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medincell SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medincell SA compared to its peers.

Compare the P/E ratios
of Medincell SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Medincell SA with its peers.

Analyze the financial leverage
of Medincell SA compared to its main competitors.

Show all profitability ratios
for Medincell SA.

Provide ROE
for Medincell SA.

Provide ROA
for Medincell SA.

Provide ROIC
for Medincell SA.

Provide ROCE
for Medincell SA.

Provide Gross Margin
for Medincell SA.

Provide Operating Margin
for Medincell SA.

Provide Net Margin
for Medincell SA.

Provide FCF Margin
for Medincell SA.

Show all solvency ratios
for Medincell SA.

Provide D/E Ratio
for Medincell SA.

Provide D/A Ratio
for Medincell SA.

Provide Interest Coverage Ratio
for Medincell SA.

Provide Altman Z-Score Ratio
for Medincell SA.

Provide Quick Ratio
for Medincell SA.

Provide Current Ratio
for Medincell SA.

Provide Cash Ratio
for Medincell SA.

What is the historical Revenue growth
over the last 5 years for Medincell SA?

What is the historical Net Income growth
over the last 5 years for Medincell SA?

What is the current Free Cash Flow
of Medincell SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Medincell SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medincell SA

Current Assets 27.3m
Cash & Short-Term Investments 19.5m
Receivables 6.7m
Other Current Assets 1.1m
Non-Current Assets 9.7m
Long-Term Investments 1.8m
PP&E 5.4m
Intangibles 2.5m
Current Liabilities 16.5m
Accounts Payable 1.8m
Accrued Liabilities 3.2m
Other Current Liabilities 11.5m
Non-Current Liabilities 61.3m
Long-Term Debt 52.8m
Other Non-Current Liabilities 8.5m
Efficiency

Earnings Waterfall
Medincell SA

Revenue
9m EUR
Cost of Revenue
-2.3m EUR
Gross Profit
6.8m EUR
Operating Expenses
-27.6m EUR
Operating Income
-20.8m EUR
Other Expenses
-4.2m EUR
Net Income
-25m EUR

Free Cash Flow Analysis
Medincell SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MEDCL Profitability Score
Profitability Due Diligence

Medincell SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional ROE
47/100
Profitability
Score

Medincell SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

MEDCL Solvency Score
Solvency Due Diligence

Medincell SA's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
31/100
Solvency
Score

Medincell SA's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MEDCL Price Targets Summary
Medincell SA

Wall Street analysts forecast MEDCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDCL is 22.29 EUR with a low forecast of 18.48 EUR and a high forecast of 25.2 EUR.

Lowest
Price Target
18.48 EUR
6% Upside
Average
Price Target
22.29 EUR
28% Upside
Highest
Price Target
25.2 EUR
45% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MEDCL?

Click here to dive deeper.

Dividends

Medincell SA
does not pay dividends
Shareholder Yield

Current shareholder yield for MEDCL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MEDCL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Medincell SA Logo
Medincell SA

Country

France

Industry

Pharmaceuticals

Market Cap

506.4m EUR

Dividend Yield

0%

Description

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

Contact

OCCITANIE
Jacou
3 Rue des Freres Lumiere
+33467021367.0
www.medincell.com

IPO

2018-10-08

Employees

150

Officers

Chief Executive Officer & Director
Mr. Christophe Douat
Chief People Officer & Member of the Management Board
Mr. Franck Pouzache
Chief Financial Officer
Mr. Stephane Postic
Head of Legal
Julie Alimi
Head of Communications
Mr. David Heuze
Head of Research & Development
Mr. Adolfo Lopez-Noriega
Show More
Chief Business Officer
Mr. Sebastien Enault
Head of Alliance & Project Management
Ms. Helen Martin
Head of Global Health Development
Ms. Quiterie De Beauregard
Chief Medical Officer
Dr. Richard Malamut M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MEDCL stock?

The intrinsic value of one MEDCL stock under the Base Case scenario is 26.36 EUR.

Is MEDCL stock undervalued or overvalued?

Compared to the current market price of 17.42 EUR, Medincell SA is Undervalued by 34%.

Back to Top